HIV impairs TNF-α release in response to toll-like receptor 4 stimulation in human macrophages in vitro

American Journal of Respiratory Cell and Molecular Biology

Volumn 33, Issue 6, 2005, Pages 610-621

  Tachado, Souvenir D ^a   Zhang, Jianmin ^a   Zhu, Jinping ^a   Patel, Naimish ^a   Koziel, Henry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Alveolar macrophages; Innate immunity; Lipid A; MAP kinase; MAP kinase phosphatase 1

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; LIGAND; LIPID A; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEF PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL PNEUMONIA; CELL STIMULATION; CELL STRAIN U937; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE SILENCING; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROVOCATION TEST; SIGNAL TRANSDUCTION;

CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE PRODUCTS, NEF; GENE SILENCING; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMEDIATE-EARLY PROTEINS; LIPID A; MACROPHAGES; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; PULMONARY ALVEOLI; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 28644442415     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2004-0341OC     Document Type: Article

References (58)

1. Ashley EA, Johnson MA, Lipman MC. Human immunodeficiency virus and respiratory infection. Curr Opin Pulm Med 2000;6:240-245.
2. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, Kvale PA, Mangura BT, Reichman LB, Hopewell PC. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997;155:72-80.
3. Biswas P, Mantelli B, Delfanti F, Cota M, Vallanti G, de Filippi C, Mengozzi M, Vicenzi E, Lazzarin A, Poli G. Tumor necrosis factor-alpha drives HIV-1 replication in U937 cell clones and upregulates CXCR4. Cytokine 2001;13:55-59.
4. Benito N, Rano A, Moreno A, Gonzalez J, Luna M, Agusti C, Danes C, Pumarola T, Miro JM, Torres A, et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001;27:35-43.
5. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
6. Cordera E, Pachon J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, Torres-Tortosa M, Gonzalez-Serrano M, Aliaga L, Collado A, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med 2000;162:2063-2068.
7. Vidal F, Mensa J, Martinez JA, Almela M, Marco F, Gatell JM, Richart C, Soriano E, Jimenez de Anta MT. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999;18:473-477.
8. Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 1984;251:1447-1449.
9. Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001;11:304-311.
10. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522-1526.
11. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
12. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ. Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol 2001;69:1036-1044.
13. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164:5998-6004.
14. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, Millar AB. Expression of functional Toll-like receptor (TLR-)2 and TLR-4 on alveolar epithelial cells. Am J Respir Cell Mol Biol 2004;31:241-245.
15. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
16. Branger J, Knapp S, Weijer S, Leemans JC, Pater JM, Speelman P, Florquin S, van der Poll T. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect Immun 2004;72:788-794.
17. Wang X, Moser C, Louboutin JP, Lysenko ES, Weiner DJ, Weiser JN, Wilson JM. Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J Immunol 2002; 168:810-815.
18. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000;12:20-26.
19. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300:1524-1525.
20. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-756.
21. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990;141:471-501.
22. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J, van Rooijen N, van der Poll T. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003;167:171-179.
23. Greenberg S, Grinstein S. Phagocytosis and innate immunity. Curr Opin Immunol 2002;14:136-145.
24. Koziel H, Kim S, Reardon C, Li X, Garland R, Pinkston P, Kornfeld H. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999;160:2048-2055.
25. Park IW, Koziel H, Hatch W, Li X, Du B, Groopman JE. CD4 receptor-dependent entry of human immunodeficiency virus type-1 envpseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor. Am J Respir Cell Mol Biol 1999;20:864-871.
26. Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998; 10:363-372.
27. Gordon SB, Molyneux ME, Boeree MJ, Kanyanda S, Chaponda M, Squire SB, Read RC. Opsonic phagocytosis of Streptococcus pneumoniae by alveolar macrophages is not impaired in human immunodeficiency virus-infected Malawian adults. J Infect Dis 2001;184:1345-1349.
28. Elssner A, Carter IE, Yunger TM, Wewers MD. HIV-1 infection does not impair human alveolar macrophage phagocytic function unless combined with cigarette smoking. Chest 2004;125:1071-1076.
29. Equils O, Faure E, Thomas L, Bulut Y, Trushin S, Arditi M. Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4. J Immunol 2001;166:2342-2347.
30. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G, Fauci AS. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 1988;140:1117-1122.
31. Venema RC, Venema VJ, Eaton DC, Marrero MB. Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1. J Biol Chem 1998;273:30795-30800.
32. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-97.
33. Means TK, Pavlovich RP, Roca D, Vermeulen MW, Fenton MJ. Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J Leukoc Biol 2000;67:885-893.
34. Tanoue T, Moriguchi T, Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J Biol Chem 1999;274:19949- 19956.
35. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002;169:6408-6416.
36. Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A, Liu Y. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005;280:8101-8108.
37. Lee KH, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG. Preheating accelerates mitogen-activated protein (MAP) kinase inactivation post-heat shock via a heat shock protein 70-mediated increase in phosphorylated MAP kinase phosphatase-1. J Biol Chem 2005;280:13179-13186.
38. Zhang J, Zhu J, Imrich A, Cushion M, Kinane TB, Koziel H. Pneumocystis activates human alveolar macrophage NF-kappaB signaling through mannose receptors. Infect Immun 2004;72:3147-3160.
39. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003;424:213-219.
40. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12:186-192.
41. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
42. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997;272:16917-16923.
43. Equils O, Schito ML, Karahashi H, Madak Z, Yarali A, Michelsen KS, Sher A, Arditi M. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J Immunol 2003;170:5159-5164.
44. Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA. Signaling through toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol 2004;172:4391-4401.
45. Mathys JM, Melanson SM, Schiffer-Alberts DJ, Ioannidis JP, Koziel H, Skolnik PR. NF-kappa B modulates TNF-alpha production by alveolar macrophages in asymptomatic HIV-seropositive individuals. J Immunol 2000;164:1588-1594.
46. Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003;2:445-451.
47. Moore TA, Lau HY, Cogen AL, Monteleon CL, Standiford TJ. Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury. Shock 2003;20:309-315.
48. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
49. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996;64:4733-4738.
50. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998;280:1880-1884.
51. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001;410:834-838.
52. Bandres JC, Ratner L. Human immunodeficiency virus type 1 Nef protein down-regulates transcription factors NF-kappa B and AP-1 in human T cells in vitro after T-cell receptor stimulation. J Virol 1994;68:3243-3249.
53. Quaranta MG, Tritarelli E, Giordani L, Viora M. HIV-1 Nef induces dendritic cell differentiation: a possible mechanism of uninfected CD4(+) T cell activation. Exp Cell Res 2002;275:243-254.
54. Caldwell RL, Egan BS, Shepherd VL. HIV-1 Tat represses transcription from the mannose receptor promoter. J Immunol 2000;165:7035-7041.
55. Bour S, Perrin C, Akari H, Strebel K. The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 2001; 276:15920-15928.
56. Wallace JM, Rao AV, Glassroth J, Hansen NI, Rosen MJ, Arakaki C, Kvale PA, Reichman LB, Hopewell PC. Respiratory illness in persons with human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. Am Rev Respir Dis 1993;148:1523-1529.
57. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
58. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tp12/ ERK-dependent pathway. Cell 2000;103:1071-1083.